Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02441075
Other study ID # 14-00028
Secondary ID
Status Completed
Phase N/A
First received April 30, 2015
Last updated January 28, 2016
Start date May 2014
Est. completion date January 2016

Study information

Verified date January 2016
Source Nationwide Children's Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is for a study for patients that will be undergoing hematopoietic stem cell transplant (HSCT). For HSCT, patients will need a double lumen central venous line (CVL). One of the most common complications after an HSCT is Graft Versus Host Disease (GVHD).Tacrolimus or Cyclosporine along with methotrexate are used together in order to prevent GVHD. Normally these medications are given via the white lumen and blood is drawn via the unexposed red lumen to check the blood level of these medications. If these drugs are accidentally given via the wrong lumen (line) it could cause blood levels to be falsely high. This error could lead to the patient having to have peripheral blood draws that cause pain. The investigators are proposing adding an ethanol lock to your lumens (lines) to see if this would help clean the lines therefore preventing errors in blood tests and blood draws. An ethanol lock is a 70% alcohol which is injected into the CVL lumen and stays within the CVL as the CVL is capped.


Description:

As cyclosporine and tacrolimus are both oil based medications and ethanol (70% alcohol) can dissolve oil, the investigators hypothesize that an alcohol lock instilled into the lumen of the CVL will be able to dissolve and leach out the oil based CNI adhering to the inside lumen of the CVL catheter, thus decontaminating it. The safety of using ethanol via CVL is already proven over the last many years. A study performed with neonates resulted in no adverse effects when using ethanol locks, proving that their use is safe for the pediatric population. Ethanol has been used as locks for disinfecting CVLs infected with a broad range of microorganisms in pediatrics. It has also been useful in treating catheter occlusions caused by Lipid formation. By placing a 70% ethanol lock for two hours in the contaminated lumen, it has shown to degrade the biofilm and fat formation allowing for further use of the CVL used 70 % ethanol locks and did not find any reductions in mechanical integrity of polyetherurethane or silicone catheters exposed for as long as 10 weeks. Also, no structural integrity complications have been found in the literature along with no evidence of systemic toxicity with the use of ethanol locks. A retrospective study on PICU patients who had received ethanol locks for 12-24 hours per lumen and a repeat lock when venous access was not limited, flushed 0.2-1mls of ethanol through the catheter at the end of the dwell instead of withdrawing the lock. Sixteen patients who received five daily ethanol lock treatments in succession, had liver enzymes measured and only two patients had mildly elevated transaminases, but these levels were not significant from their baseline levels. There were also no reports from the nurses of any patient complaints or side effects. The study stated that when larger volumes in which they classified as 2.3mls of ethanol are flushed through the central line, patients have reported flushing, light-headedness, headache, nausea and dyspnea. Only 2mls of ethanol will be administered in this study, and the ethanol lock will be withdrawn prior to drawing the levels. Therefore, no side effects are expected.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Both
Age group 3 Months to 30 Years
Eligibility Inclusion Criteria:

- All patients' ages 3 months to 30 years will be eligible for the study.

- All patients undergoing an allogeneic HSCT and receiving intravenous cyclosporine or tacrolimus through a CVL will be eligible.

Exclusion Criteria:

- Patients who are hemodynamically compromised or needing intensive care in the ICU.

- Family/patient not willing to sign an informed consent.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • GVHD
  • Hematopoietic Stem Cell Transplant

Intervention

Other:
70% Ethanol
the study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.

Locations

Country Name City State
United States Nationwide Children's Hospital Columbus Ohio

Sponsors (2)

Lead Sponsor Collaborator
Nationwide Children's Hospital Daisy Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Outcome: Serum Levels Serum levels from both lumens will be compared after 2-hour ethanol lock placements. If the mean serum levels drawn at 8pm from both lumens are equivalent, the intervention will be considered effective. 18 months Yes
See also
  Status Clinical Trial Phase
Completed NCT02942173 - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT Phase 2/Phase 3
Terminated NCT01940796 - Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) Phase 1
Completed NCT02066051 - IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD N/A
Not yet recruiting NCT05544448 - In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases N/A
Completed NCT01295710 - Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Phase 3
Not yet recruiting NCT06000982 - Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis Phase 3
Not yet recruiting NCT06075225 - MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib Phase 2
Active, not recruiting NCT03680092 - Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation Phase 2
Not yet recruiting NCT06083129 - Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Phase 3
Not yet recruiting NCT05094765 - Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD Early Phase 1
Active, not recruiting NCT05415410 - Proof-of-concept Trial of Apraglutide in GVHD Phase 2
Completed NCT02588339 - Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention Phase 2
Not yet recruiting NCT06334367 - Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT Phase 2
Completed NCT03846479 - Itacitinib for Low Risk GVHD Phase 2
Completed NCT02891603 - A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression Phase 1/Phase 2
Completed NCT02712762 - Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients
Completed NCT03945591 - High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Phase 2
Not yet recruiting NCT06411184 - Safety and Efficacy of Treg Cell in the Treatment of GVHD Phase 1/Phase 2
Terminated NCT02338232 - Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT02156479 - Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients